ValiSeek Limited, the joint venture between ValiRx Plc (LON:VAL) and Tangent Reprofiling Limited, has received notification of a New Zealand patent grant allowance.
The patent, granted in the US as patent US9072743 on 14 May 2015, covers both the formulation of VAL401 and its use as a treatment against hormone-related cancers, including lung cancer.
More on the VAL401 US patent approval
Watch: Dr Suzy Dilly, co-inventor of VAL401 and chief scientific officer of ValiRx, talking about the drug
"This is the first non-US patent grant allowance received for the VAL401 project and, as such, it provides an international validation of the programme to support world-wide commercialisation," said Dr Suzanne Dilly, the chief executive officer of ValiSeek Limited.